Literature DB >> 5129377

Metabolites of naloxone in human urine.

S H Weinstein, M Pfeffer, J M Schor, L Indindoli, M Mintz.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1971        PMID: 5129377     DOI: 10.1002/jps.2600601030

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


× No keyword cloud information.
  7 in total

Review 1.  Naloxone dosage for opioid reversal: current evidence and clinical implications.

Authors:  Rachael Rzasa Lynn; J L Galinkin
Journal:  Ther Adv Drug Saf       Date:  2017-12-13

2.  Nalmefene is effective at reducing alcohol seeking, treating alcohol-cocaine interactions and reducing alcohol-induced histone deacetylases gene expression in blood.

Authors:  Javier Calleja-Conde; Victor Echeverry-Alzate; Elena Giné; Kora-Mareen Bühler; Roser Nadal; Rafael Maldonado; Fernando Rodríguez de Fonseca; Antoni Gual; Jose Antonio López-Moreno
Journal:  Br J Pharmacol       Date:  2016-07-18       Impact factor: 8.739

3.  Degree and duration of reversal by naloxone of effects of morphine in conscious subjects.

Authors:  J M Evans; M I Hogg; J N Lunn; M Rosen
Journal:  Br Med J       Date:  1974-06-15

4.  Naloxone pharmacokinetics in the newborn.

Authors:  T A Moreland; J E Brice; C H Walker; A C Parija
Journal:  Br J Clin Pharmacol       Date:  1980-06       Impact factor: 4.335

5.  Oxycodone/Naloxone: role in chronic pain management, opioid-induced constipation, and abuse deterrence.

Authors:  Anne Z DePriest; Katie Miller
Journal:  Pain Ther       Date:  2014-05-06

6.  Absorption, distribution, metabolism, and excretion of [14C]-labeled naloxegol in healthy subjects.

Authors:  Khanh Bui; Fahua She; Michael Hutchison; Åsa Brunnström; Mark Sostek
Journal:  Int J Clin Pharmacol Ther       Date:  2015-10       Impact factor: 1.366

7.  The pharmacokinetic interaction between nasally administered naloxone and the opioid remifentanil in human volunteers.

Authors:  Ida Tylleskar; Sissel Skarra; Arne Kristian Skulberg; Ola Dale
Journal:  Eur J Clin Pharmacol       Date:  2021-07-29       Impact factor: 2.953

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.